Navigation Links
Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate
Date:10/25/2010

SAN DIEGO, Oct. 25 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). The patent can be viewed on the USPTO's website at www.uspto.gov. Trius also has licensed patents in Australia, New Zealand, and India, and a patent application in Russia where a notice of allowance was recently issued.  Counterpart applications are also pending in additional territories.

"The issuance of this patent adds to our robust intellectual property portfolio for torezolid phosphate, the only second-generation oxazolidinone in Phase 3 development," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius.  "These issued claims are expected to provide patent exclusivity for torezolid phosphate through late 2026."

Trius acquired worldwide rights outside of North and South Korea to a family of patent applications that provide patent coverage for composition of matter and methods of making and using torezolid phosphate through an exclusive license from Dong-A Pharmaceuticals in 2007.  In addition to the U.S. patent and the four allowed or issued foreign patents mentioned above, Trius has filed patent applications directed to other aspects of torezolid phosphate discovered by Trius' scientists. Patents which may issue from these additional applications could provide patent exclusivity for torezolid phosphate through 2030.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused o
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA
2. Trius to Present at the Stifel Nicolaus Healthcare Conference
3. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
4. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
5. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
6. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
7. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
8. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Trius Doses First Patient in Antibacterial Phase 2 Trial
11. PacificGMP Completes GMP Product Fill for Trius Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:4/23/2014)... is looking to give exercise enthusiasts the extra nudge ... shows that a cyber buddy can help. , The ... Journal , is the first to indicate that although ... exercise, a software-generated partner also can be effective. , ... can still motivate people to give greater effort while ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
Breaking Medicine News(10 mins):Health News:Cyber buddy is better than 'no buddy' 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2
... the overweight , , MONDAY, March 3 (HealthDay News) -- ... to have breathing-related problems during surgery, says a University ... looked at 1,380 normal-weight, 351 overweight, and 294 obese ... surgery, found that obese children had a higher rate ...
... WASHINGTON, March 3 To commemorate Patient,Safety Awareness Week ... Epidemiology (APIC) is issuing five steps every,patient can take ... of,developing an infection during a hospital stay., Visit ... learn,more., 1) First Step, Hospital Prep, Most ...
... and advocate for affordable health coverage. Health, labor, faith ... ... Leaders from throughout Michigan,including representatives of insurers, health systems, labor, ... newly formed,Michigan Cover The Uninsured Network (MCTUN). The goal of the ...
... Smith & Nephew,Inc.,s (NYSE: SNN ; ... approval of its award winning OXINIUM(TM),oxidized zirconium technology., ... company to offer such a,revolutionary and award winning ... alloy with a ceramic bearing surface. OXINIUM,provides low ...
... OrthoSynetics(TM), the largest,provider of business services to orthodontic ... Director, IT Infrastructure., "Hiring Brad is in ... and providing the most innovative technology to,our doctors ... CEO,OrthoSynetics(TM). "In a very short period of time, ...
... Super Bowl champ O.J. Brigance,who recently confirmed a ... at The Robert Packard Center for ALS Research ... by the Center to fund,research to find a ... Gehrig,s,Disease.", (Photo: http://www.newscom.com/cgi-bin/prnh/20080303/NEM042 ), ...
Cached Medicine News:Health News:Obese Children Face More Complications During Surgery 2Health News:APIC Issues Recommendations on How to Have a Healthy Hospital Stay 2Health News:Michigan Leaders Join Network to Push for Coverage of State's 1.4 Million Uninsured 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 3Health News:Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure 2Health News:O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Determination of FDP in Plasma by Latex Agglutination, 60 tests.Microlatex particles coated with mouse monoclonal anti-human FDP antibodies....
Medicine Products: